Establishment of a nomogram for survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation

Abstract

Objective To establish a nomogram for overall survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation of Chinese data. Methods The data of 1809 patients, registered in National Cancer Institute SEER database in 2004-2015, who underwent hepatectomy for primary small hepatocellular carcinoma were extracted as modeling group, and 158 patients with small hepatocellular carcinoma who underwent hepatectomy in Affiliated Hospital of North Sichuan Medical College from 2010 to 2017 were collected as validation group. The univariate Cox risk regression analysis, lasso regression analysis, and multivariate Cox hazard regression analysis were used to investigate the influencing factors for OS after hepatectomy in patients with small hepatocellular carcinoma. A nomogram was established based on the independent influencing factors for OS, and index of concordance (C-index), calibration curves, and receiver operating characteristic (ROC) curve were used to analyze the predictive ability of the nomogram. The Kaplan-Meier survival analysis and the log-rank test were used to investigate the difference in survival between the high- and low-risk groups. Results The multivariate Cox hazard regression analysis showed that sex (hazard ratio [HR]=1.22, 95% confidence interval [CI]: 1.05-1.41, P=0.010), Seer stage (HR=1.51, 95%CI: 1.23-1.85, P < 0.001; HR=10.31, 95%CI: 2.53-42.04, P=0.001), tumor diameter (HR=1.22, 95%CI: 1.06-1.39, P=0.004), vascular invasion or metastasis (HR=1.43, 95%CI: 1.24-1.65, P < 0.001), and alpha-fetoprotein (HR=1.33, 95%CI: 1.16-1.54, P < 0.001) were independent risk factors for OS after hepatectomy for small hepatocellular carcinoma. The modeling group had a C-index of 0.621, and its area under the ROC curve at 1, 2, and 3 years was 0.666(95%CI 0.628-0.704), 0.678(95%CI 0.647-0.708), and 0.663(95%CI: 0.635-0.690), respectively; the validation group had a C-index of 0.718, and its area under the ROC curve at 1, 2, and 3 years was 0.695(95%CI: 0.593-0.797), 0.781(95%CI: 0.706-0.856), and 0.759(95%CI 0.669-0.848), respectively. Risk stratification was performed based on the nomogram, and the Kaplan-Meier survival analysis showed that for both the modeling group and the validation group, the low-risk group had a significantly better prognosis than the high-risk group (P < 0.01). Conclusion The model established for survival rate after liver resection for primary small hepatocellular carcinoma can predict the 1-, 2-, and 3-year OS rates and can thus be used in clinical practice in China.
- Carcinoma, Hepatocellular,
- Hepatectomy,
- Nomograms

FullText(HTML)

References(27)

References

[1]	TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262.
[2]	WEN T, JIN C, FACCIORUSSO A, et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: An international expert consensus[J]. Hepatobiliary Surg Nutr, 2018, 7(5): 353-371. DOI: 10.21037/hbsn.2018.08.01.
[3]	AHN KS, KANG KJ. Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?[J]. Clin Mol Hepatol, 2019, 25(4): 354-359. DOI: 10.3350/cmh.2018.0096.
[4]	LI CH, HU P, OU YJ, et al. Development and validation of nomogram for predicting survival outcomes in patients with small hepatocellular carcinoma[J]. J Third Mil Med Univ, 2020, 42(20): 2046-2056. DOI: 10.16016/j.1000-5404.202007005. 李传红, 胡鹏, 欧晏娇, 等. 预测小肝癌患者生存率列线图的建立和验证[J]. 第三军医大学学报, 2020, 42(20): 2046-2056. DOI: 10.16016/j.1000-5404.202007005.
[5]	ZHANG W, WANG X, JIANG R, et al. Effect of tumor size on cancer-specific survival in small hepatocellular carcinoma[J]. Mayo Clin Proc, 2015, 90(9): 1187-1195. DOI: 10.1016/j.mayocp.2015.06.018.
[6]	WEI Y, DAI F, YI Y, et al. Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas[J]. Oncol Lett, 2018, 16(4): 5050-5058. DOI: 10.3892/ol.2018.9263.
[7]	VOLK ML. Unfair priority for HCC: A problem whose ideal solution remains unsolved[J]. Am J Transplant, 2010, 10(7): 1507-1508. DOI: 10.1111/j.1600-6143.2010.03154.x.
[8]	ZANG YY, LONG PY, HAN ZW, et al. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(10): 2225-2230. DOI: 10.3969/j.issn.1001-5256.2019.10.019. 臧游亚, 龙沛雲, 韩志伟, 等. 肝细胞癌患者肝切除术后预后列线图的建立与验证[J]. 临床肝胆病杂志, 2019, 35(10): 2225-2230. DOI: 10.3969/j.issn.1001-5256.2019.10.019.
[9]	SALVATORE M, JEON J, MEZA R. Changing trends in liver cancer incidence by race/ethnicity and sex in the US: 1992-2016[J]. Cancer Causes Control, 2019, 30(12): 1377-1388. DOI: 10.1007/s10552-019-01237-4.
[10]	BALACHANDRAN VP, GONEN M, SMITH JJ, et al. Nomograms in oncology: More than meets the eye[J]. Lancet Oncol, 2015, 16(4): e173-e180. DOI: 10.1016/S1470-2045(14)71116-7.
[11]	JADLOWIEC CC, TANER T. Liver transplantation: Current status and challenges[J]. World J Gastroenterol, 2016, 22(18): 4438-4445. DOI: 10.3748/wjg.v22.i18.4438.
[12]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[13]	AN L, ZENG HM, ZHENG RS, et al. Liver cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(10): 721-722. DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001. 安澜, 曾红梅, 郑荣寿, 等. 2015年中国肝癌流行情况分析[J]. 中华肿瘤杂志, 2019, 41(10): 721-722. DOI: 10.3760/cma.j.issn.0253-3766.2019.10.001.
[14]	CHEN K, HUO RR, CHEN SY, et al. Analysis of the relationship between gender and prognosis of patients after liver resection for hepatocellular carcinoma[J]. Chin J Hepatobiliary Surg, 2020, 26(5): 330-334. DOI: 10.3760/cma.j.cn113884-20190909-00290. 陈康, 霍荣瑞, 陈肃伊, 等. 性别对肝细胞癌患者肝切除术后预后的影响[J]. 中华肝胆外科杂志, 2020, 26(5): 330-334. DOI: 10.3760/cma.j.cn113884-20190909-00290.
[15]	GALLE PR, FOERSTER F, KUDO M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2214-2229. DOI: 10.1111/liv.14223.
[16]	ZHU Y, XIA QQ, LUO J, et al. Application of combined detection of alpha-fetoprotein, alpha-fetoprotein heterogeneity and TNF-α factor in the diagnosis of primary liver cancer and its clinical value[J]. J Clin Exp Med, 2020, 19(4): 383-386. DOI: 10.3969/j.issn.1671-4695.2020.04.014. 朱艳, 夏芹芹, 罗俊, 等. 甲胎蛋白、甲胎蛋白异质体与TNF-α因子联合检测在原发性肝癌诊断中的应用价值[J]. 临床和实验医学杂志, 2020, 19(4): 383-386. DOI: 10.3969/j.issn.1671-4695.2020.04.014.
[17]	GRAHAM JA, MELANCON JK, SHETTY K, et al. Liver transplantation should be offered to patients with small solitary hepatocellular carcinoma and a positive serum alpha fetoprotein rather than resection[J]. Am J Surg, 2013, 205(4): 374-380. DOI: 10.1016/j.amjsurg.2012.12.002.
[18]	TANG H, TANG XY, LIU M, et al. Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle[J]. Clin Chim Acta, 2008, 394(1-2): 81-88. DOI: 10.1016/j.cca.2008.04.012.
[19]	LU Y, ZHU M, LI W, et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells[J]. J Cell Mol Med, 2016, 20(3): 549-558. DOI: 10.1111/jcmm.12745.
[20]	ZHANG XP, CHEN ZH, ZHOU TF, et al. A nomogram to predict early postoperative recurrence of hepatocellular carcinoma with portal vein tumour thrombus after R0 liver resection: A large-scale, multicenter study[J]. Eur J Surg Oncol, 2019, 45(9): 1644-1651. DOI: 10.1016/j.ejso.2019.03.043.
[21]	WANG Y, SUN K, SHEN J, et al. Novel prognostic nomograms based on inflammation-related markers for patients with hepatocellular carcinoma underwent hepatectomy[J]. Cancer Res Treat, 2019, 51(4): 1464-1478. DOI: 10.4143/crt.2018.657.
[22]	YUAN SX, ZHOU WP. Progress and hot spots of comprehensive treatment for primary liver cancer[J]. Chin J Dig Surg, 2021, 20(2) : 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776. 袁声贤, 周伟平. 原发性肝癌综合治疗的进展和热点[J]. 中华消化外科杂志, 2021, 20(2): 163-170. DOI: 10.3760/cma.j.cn115610-20201211-00776.
[23]	LU XY, XI T, LAU WY, et al. Pathobiological features of small hepatocellular carcinoma: Correlation between tumor size and biological behavior[J]. J Cancer Res Clin Oncol, 2011, 137(4): 567-575. DOI: 10.1007/s00432-010-0909-5.
[24]	MINAGAWA M, IKAI I, MATSUYAMA Y, et al. Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13, 772 patients in Japan[J]. Ann Surg, 2007, 245(6): 909-922. DOI: 10.1097/01.sla.0000254368.65878.da.
[25]	ZHOU DD, LIU XL, JIANG TT, et al. Analysis and comparison of common prognostic prediction models for liver cancer[J]. Chin J Clin Oncol, 2020, 47(24): 1281-1286. DOI: 10.3969/j.issn.1000-8179.2020.24.149. 周冬冬, 刘晓利, 姜婷婷, 等. 常见肝癌预后预测模型的分析与比较[J]. 中国肿瘤临床, 2020, 47(24): 1281-1286. DOI: 10.3969/j.issn.1000-8179.2020.24.149.
[26]	WEN L, WENG S, YAN C, et al. A radiomics nomogram for preoperative prediction of early recurrence of small hepatocellular carcinoma after surgical resection or radiofrequency ablation[J]. Front Oncol, 2021, 11: 657039. DOI: 10.3389/fonc.2021.657039.
[27]	ZHOU ZW, LIU YC, XIANG BD, et al. Global outlook for primary liver cancer: Prevalence, risk, factors and population attribution scores[J]. Chin J Oncol Prev Treat, 2021, 13(1): 14-21. DOI: 10.3969/j.issn.1674-5671.2021.01.03. 周泽文, 刘颖春, 向邦德, 等. 原发性肝癌的全球展望: 流行情况、危险因素和人群归因分值[J]. 中国癌症防治杂志, 2021, 13(1): 14-21. DOI: 10.3969/j.issn.1674-5671.2021.01.03.

Relative Articles

[1]	Yangqing MA, Haina FAN, Xin SUN, Chenghai LIU. Role of Golgi protein 73(GP73) in diagnosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(8): 1999-2004. doi: 10.3969/j.issn.1001-5256.2023.08.035
[2]	Hang ZHANG, Jinchun LIU. Role of serum Golgi protein 73 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(3): 657-662. doi: 10.3969/j.issn.1001-5256.2023.03.028
[3]	Peiling YE, Hongyun JIA, Liang PENG. Mechanism of action of GP73 in the regulation of liver cancer: An analysis based on transcriptome sequencing[J]. Journal of Clinical Hepatology, 2021, 37(8): 1861-1866. doi: 10.3969/j.issn.1001-5256.2021.08.022
[4]	Luo WenPing, Ma Hong, Wang Yu. Advances in the application of transient elastography in noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(3): 635-639. doi: 10.3969/j.issn.1001-5256.2019.03.041
[5]	Zheng ShaoQiu, Wang QiZhi. Current status and prospects of research on noninvasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2019, 35(1): 197-200. doi: 10.3969/j.issn.1001-5256.2019.01.043
[6]	Zhang LiJun, Liu MingJun, Wang Shuai, Wang Lin, Wang RuKun, Hou HuaBin, Sun GuiRong, Zhang NaNa, Liu LinJie. Clinical value of Golgi protein 73 and hyaluronic acid in diagnosis of the progression of hepatitis B virus-related chronic liver diseases[J]. Journal of Clinical Hepatology, 2018, 34(1): 63-67. doi: 10.3969/j.issn.1001-5256.2018.01.013
[7]	Yao MingJie, Wang LeiJie, Guan GuiWen, Xi JingYuan, Liu ShuHong, Wen XiaJie, Zou Jun, Chen XiangMei, Jia JiDong, Zhao JingMin, Lu FengMin. Value of serum Golgi protein 73 in assisting the diagnosis of moderate or severe liver injury in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(4): 755-759. doi: 10.3969/j.issn.1001-5256.2018.04.012
[8]	Zhao YunSheng, Zhang LiNa, Huo LiJing, Pei Liu, Li QiuPing, Li HongChen, Jin Liang. Clinical value of fucosylated Golgi protein 73 in differential diagnosis of small hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(8): 1707-1711. doi: 10.3969/j.issn.1001-5256.2018.08.023
[9]	Lu FengMin. Serological diagnosis of hepatocellular carcinoma:challenges and opportunities[J]. Journal of Clinical Hepatology, 2017, 33(7): 1262-1265. doi: 10.3969/j.issn.1001-5256.2017.07.011
[10]	Yang ErNa, Cao WuKui. Research advances in noninvasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2209-2213. doi: 10.3969/j.issn.1001-5256.2017.11.035
[11]	Wei FengXian, Liu Zhao, Geng Jie, Su GuoHong, Chen Mo, Wang ManCai, Cao WeiJia, Zhang YouCheng. Research advances in association between Golgi protein 73 and liver diseases[J]. Journal of Clinical Hepatology, 2017, 33(8): 1595-1598. doi: 10.3969/j.issn.1001-5256.2017.08.040
[12]	Yang YiLiang, Cui YuanYuan, Hu Yue, Xu HongQin, Pan Yu. Role of the Mac-2 binding protein glycosylation isomer in diagnosis of chronic liver diseases[J]. Journal of Clinical Hepatology, 2016, 32(12): 2395-2398. doi: 10.3969/j.issn.1001-5256.2016.12.036
[13]	Yang MingLei, Yao DingKang. Application of magnetic resonance elastography as a non-invasive technique for diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(3): 588-592. doi: 10.3969/j.issn.1001-5256.2016.03.042
[14]	Zhao Wei. Clinical significance of plasma and urine neutrophil gelatinase-associated lipocalin levels in diagnosis of acute kindney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1874-1877. doi: 10.3969/j.issn.1001-5256.2015.11.025
[15]	Wu Qiong, Xu GuangHua. Recent research findings on non-invasive diagnosis of liver fibrosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 295-299. doi: 10.3969/j.issn.1001-5256.2015.02.040
[16]	Liu XiuHong, Zhao YiMing, Li Ning, Jin BoXun, Yan HuiPing, Zhao YuanShun, Li Ang, Han Zhen, Zhang AiYing. Diagnostic values of plasma Golgi protein-73 and platelet count for different stages of HBV-related liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(9): 1469-1472. doi: 10.3969/j.issn.1001-5256.2015.09.025
[17]	Zhang Qin, Dan HongLi, Xu Wei. Value of serum GP73,AFP,and AFP-L3 in diagnosis of liver cancer and recurrence monitoring after radiofrequency ablation[J]. Journal of Clinical Hepatology, 2015, 31(2): 232-235. doi: 10.3969/j.issn.1001-5256.2015.02.021
[18]	Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
[19]	Gao HaiFeng. Value of combined detection of serum AFP and GP73 in early diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(7): 660-662. doi: 10.3969/j.issn.1001-5256.2014.07.022
[20]	Zhu Chen, Sun YuanYuan, Jin Yan. Values of serum AFP, GGTⅡ and GP73 in diagnosis of primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1064-1066. doi: 10.3969/j.issn.1001-5256.2014.10.022

Supplements(0)

Cited By

Cited by

Periodical cited type(17)

1.	郭堑，农村立，韦秋芳. 慢性乙型肝炎肝纤维化患者血清Copeptin和PCT表达水平及其临床价值研究. 现代检验医学杂志. 2023(02): 112-117+189 .
2.	李初谊，王俊科，李斌，温雪，魏晓静，于晓辉. 血浆置换对慢加急性肝衰竭辅助治疗的效果评价. 海南医学院学报. 2022(16): 1228-1231 .
3.	王鑫，张国民，牛兴杰，李萍，张冰. 外周血CD14~+CD16~+单核细胞亚群在肝衰竭继发感染患者中的检测价值. 中国免疫学杂志. 2020(09): 1124-1127+1130 .
4.	姜曼蕾，许飞，胡江玲，罗嘉裕，罗方云. IL-6、CRP、PCT和内毒素预判肝衰竭合并细菌感染风险中的临床价值. 中华医院感染学杂志. 2020(20): 3062-3065 .
5.	张国民，王鑫，韩智炜，牛兴杰，刘志慧，崔凤梅. 降钙素原、白细胞介素6、sCD14、CD64检测在肝功能衰竭患者诊治中的临床研究. 中国现代医学杂志. 2019(03): 47-51 .
6.	江艳霞，骆小燕，骆旭航，龚安安，孙爱华. 血清降钙素原在胆管炎危重度早期评估中的价值研究. 中国卫生检验杂志. 2019(04): 462-463+468 .
7.	张国民，韩智炜，牛兴杰，刘志慧，王鑫. IL-6、CD14、CD64检测在感染所致肝衰竭患者中意义. 现代医学. 2019(02): 137-140 .
8.	黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 .
9.	杨丽霞，张伦理，赖玲玲，方铭. 腹水中肝素结合蛋白及降钙素原对肝硬化腹水伴自发性细菌性腹膜炎的诊断价值. 临床肝胆病杂志. 2019(06): 1266-1269 . 本站查看
10.	李薇，任小丹，何谦，周荣幸. 血清降钙素原检测对胆道梗阻合并感染者的预测价值. 中华实验和临床感染病杂志(电子版). 2019(03): 245-249 .
11.	张国民，韩智炜，牛兴杰，刘志慧，崔凤梅，王鑫. PCT、IL-6、CD14、CD64及TNF-α表达对肝衰竭合并医院感染患者预后的影响. 中华医院感染学杂志. 2019(16): 2450-2453 .
12.	王鑫，张国民，牛兴杰，李萍，张冰. 肝衰竭继发感染患者外周血Toll样受体4及降钙素原、C反应蛋白变化情况分析. 现代消化及介入诊疗. 2019(10): 1084-1087+1094 .
13.	石春霞，陈倩，王瑶，焦方舟，龚作炯. 肝功能衰竭并感染患者血清正五聚蛋白3和肝素结合蛋白及降钙素原水平变化. 中华实用诊断与治疗杂志. 2019(12): 1188-1190 .
14.	顾静，王艳，陈丽，徐英，甘建和. HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义. 临床肝胆病杂志. 2018(04): 801-805 . 本站查看
15.	王小芳，奉万盛，周红翠，邱咏佳. 血清降钙素原、白细胞计数、C-反应蛋白与细菌血培养联合检测在感染患者中的应用价值. 中国医药导报. 2018(19): 75-78 .
16.	沈素晶，邓超，李霭文，谭俊青. 不同化学发光检测系统测定PCT结果的相关性分析. 实验与检验医学. 2018(06): 873-875+891 .
17.	詹金美，林欢，孙家敏. 定量检测血清降钙素原在诊断肝衰竭患者腹腔感染细菌类型中的价值. 中外医疗. 2017(28): 34-36 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (871) PDF downloads(71)

Establishment of a nomogram for survival rate after liver resection for primary small hepatocellular carcinoma based on SEER data and external validation

DOI: 10.3969/j.issn.1001-5256.2022.01.017